AbCellera Investor Conference Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 19 UNLOCKING NEW DRUG CLASSES WITH TECH Recent acquisitions successfully integrated into our tech stack are being leveraged to unlock new programs. ; : P CD3-binding antibodies T CELL ENGAGERS GPCRs & ION CHANNELS ******/...is tumor-binding antibodies Enabled by the following acquisitions: OrthoMab Bispecific Platform Acquired in 2020 TRIANNI Acquired in 2020 TetraGenetics Acquired in 2021

View entire presentation